HTX-011 (bupivacaine and meloxicam) for the prevention of postoperative pain - clinical considerations
- PMID: 33618542
- DOI: 10.2217/pmt-2020-0097
HTX-011 (bupivacaine and meloxicam) for the prevention of postoperative pain - clinical considerations
Abstract
HTX-011 is an extended-release, dual-acting local anesthetic consisting of bupivacaine (sodium-channel blocker) and low-dose meloxicam (non-steroidal anti-inflammatory drug [NSAID]) applied needle-free during surgery. Introducing low-dose meloxicam addresses the limited efficacy of liposomal bupivacaine in acidic inflamed tissues and allows enhanced analgesic effects over three days. It has great promise to be an extremely effective postoperative pain regimen and produce an opioid-free surgical recovery, as it has consistently significantly reduced pain scores and opioid consumption through 72 h. This manuscript provides an updated, concise narrative review of the pharmacology, clinical efficacy, safety and tolerability of this drug and its applications to prevent postoperative pain.
Keywords: HTX-011; bupivacaine; local anesthetic; meloxicam; pain; postoperative pain.
Plain language summary
Lay abstract HTX-011 is a local anesthetic (a drug to induce temporary loss of sensation or awareness, usually during a medical procedure), which is made up of a combination of two drugs and applied needle-free during surgery. It has great promise to provide effective treatment for postoperative pain (pain after an operation), allowing patients to have an opioid-free option for their pain relief. This paper reviews how this drug works and the clinical trials that have taken place so far to investigate its safety and effectiveness in reducing pain after an operation.
Similar articles
-
The Role of Exparel Plus Meloxicam for Postoperative Pain Management.Curr Pain Headache Rep. 2020 Jan 30;24(3):6. doi: 10.1007/s11916-020-0837-2. Curr Pain Headache Rep. 2020. PMID: 32002676 Review.
-
Opioid-Free Recovery from Bunionectomy with HTX-011, a Dual-Acting Local Anesthetic Combining Bupivacaine and Meloxicam, as the Foundation of Non-Opioid Multimodal Analgesia.J Am Podiatr Med Assoc. 2021 May 1;111(3):Article_15. doi: 10.7547/20-204. J Am Podiatr Med Assoc. 2021. PMID: 33471086
-
Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain.Drugs. 2021 Jul;81(10):1203-1211. doi: 10.1007/s40265-021-01551-9. Epub 2021 Jul 6. Drugs. 2021. PMID: 34228280 Review.
-
Bupivacaine/meloxicam ER: A New Dual-acting Extended-Release Local Anesthetic for Opioid-Sparing Postoperative Pain Management.Ann Pharmacother. 2023 Jan;57(1):71-85. doi: 10.1177/10600280221086639. Epub 2022 May 10. Ann Pharmacother. 2023. PMID: 35536151 Review.
-
HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial.J Arthroplasty. 2020 Oct;35(10):2843-2851. doi: 10.1016/j.arth.2020.05.044. Epub 2020 May 27. J Arthroplasty. 2020. PMID: 32561266 Clinical Trial.
Cited by
-
Biomaterials and Regenerative Medicine in Pain Management.Curr Pain Headache Rep. 2022 Jul;26(7):533-541. doi: 10.1007/s11916-022-01055-5. Epub 2022 Jun 21. Curr Pain Headache Rep. 2022. PMID: 35727489 Free PMC article. Review.
-
The Options for Neuraxial Drug Administration.CNS Drugs. 2022 Aug;36(8):877-896. doi: 10.1007/s40263-022-00936-y. Epub 2022 Jul 15. CNS Drugs. 2022. PMID: 35836037 Free PMC article. Review.
-
Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews.J Clin Med. 2022 Sep 24;11(19):5628. doi: 10.3390/jcm11195628. J Clin Med. 2022. PMID: 36233497 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
